Diagnostic value of nitric oxide, lipoprotein(a), and malondialdehyde levels in the peripheral venous and cavernous blood of diabetics with erectile dysfunction

International Journal of Impotence Research

Volumn 18, Issue 6, 2006, Pages 544-549

  El Latif, M A ^a   Makhlouf, A A ^b   Moustafa, Y M ^a   Gouda, T E ^a   Niederberger, C S ^b   Elhanbly, S M ^a  

^a MANSOURA UNIVERSITY   (Egypt)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Diabetes; Impotence; Lipoprotein; Malondialdehyde; Nitric oxide

Indexed keywords

BIOCHEMICAL MARKER; CHOLESTEROL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; LIPID; LIPOPROTEIN A; MALONALDEHYDE; NITRIC OXIDE; PAPAVERINE; PHENTOLAMINE; PROSTAGLANDIN E1; TRIACYLGLYCEROL;

ADULT; ARTERIAL INSUFFICIENCY; ARTERY DIAMETER; ARTICLE; BIOASSAY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS CAVERNOSUM; CORRELATION ANALYSIS; DIABETES MELLITUS; DIAGNOSTIC VALUE; DISEASE DURATION; DISEASE SEVERITY; ECHOGRAPHY; ERECTILE DYSFUNCTION; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; PENIS ERECTION; PRIORITY JOURNAL; PSYCHOGENIC IMPOTENCE; RECEIVER OPERATING CHARACTERISTIC; SYSTOLE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BIOLOGICAL MARKERS; DIABETES COMPLICATIONS; HUMANS; IMPOTENCE; LIPOPROTEIN(A); MALE; MALONDIALDEHYDE; MICROCIRCULATION; MIDDLE AGED; NITRIC OXIDE;

EID: 33750435165     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901473     Document Type: Article

References (33)

1. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151(1): 54-61.
2. Rosen RC, Wing R, Schneider S, Gendrano 3rd N. Epidemiology of erectile dysfunction: the role of medical comorbidities and lifestyle factors. Urol Clin North Am 2005; 32: 403-417.
3. Brown JS, Wessells H, Chancellor MB, Howards SS, Stamm WE, Stapleton AE et al. Urologic complications of diabetes. Diab Care 2005; 28: 177-185.
4. Minhas S, Earley I. Diabetic impotence. In: Culley CC, Roger SK, Irwin G (eds). Textbook of Erectile Dysfunction, 1st edn. Isis Medical Media Ltd: New York, London, Barcelona, 1999, Chapter 47, pp. 541-544.
5. Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 2003; 89: 251-253.
6. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84: 9265-9269.
7. Lue TF. Erectile dysfunction. N Engl J Med 2000; 342: 1802-1813.
8. Bivalacqua TJ, Hellstrom WJ, Kadowitz PJ, Champion HC. Increased expression of arginase II in human diabetic corpus cavernosum: in diabetic-associated erectile dysfunction. Biochem Biophys Res Commun 2001; 283: 923-927.
9. Andersson KE, Hedlund P, Alm P. Sympathetic pathways and adrenergic innervation of the penis. Int J Impot Res 2000; 12(Suppl 1): S5-S12.
10. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102: 1082-1085.
11. De Young L, Yu D, Bateman RM, Brock GB. Oxidative stress and antioxidant therapy: their impact in diabetes-associated erectile dysfunction. J Androl 2004; 25: 830-836.
12. Agarwal A, Nandipati KC, Sharma RK, Zippe CD, Raina R. Role of oxidative stress in pathophysiology of erectile dysfunction. J Androl 2005; [E-pub ahead of print].
13. Piconi L, Quagliaro L, Ceriello A. Oxidative stress in diabetes. Clin Chem Lab Med 2003; 41: 1144-1149.
14. Griesmacher A, Kindhauser M, Andert SE, Schreiner W, Toma C, Knoebl P et al. Enhanced serum levels of thiobarbituric-acid-reactive substances in diabetes mellitus. Am J Med 1995; 98: 469-475.
15. Little RR, England JD, Wiedmeyer HM, McKenzie EM, Mitra R, Erhart PM et al. Interlaboratory standardization of glycated hemoglobin determinations. Clin Chem 1986; 32: 358-360.
16. Schmidt HH, Walter U. NO at work. Cell 1994; 78: 919-925.
17. Matsumoto M, Wakasugi H, Ibayashi H. Serum vitamin E, lipid peroxide and glutathione peroxidase in patients with chronic pancreatitis. Clin Chim Acta 1981; 110: 121-125.
18. Gries A, Nimpf J, Nimpf M, Wurm H, Kostner GM. Free and Apo B-associated Lpa-specific protein in human serum. Clin Chim Acta 1987; 164: 93-100.
19. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20: 470-475.
20. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2 + precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982; 28: 1379-1388.
21. Wahlefeld AW. Triglycerides determination after enzymatic hydrolysis. In: Bergmyere HW (ed). Methods of enzymatic analysis. Academic Press: New York, 1974, p. 18.
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
23. Atahan O, Kayigil O, Hizel N, Metin A. Is apolipoprotein-(a) an important indicator of vasculogenic erectile dysfunction? Int Urol Nephrol 1998; 30: 185-191.
24. Robinson LQ, Woodcock JP, Stephenson TP. Results of investigation of impotence in patients with overt or probable neuropathy. Br J Urol 1987; 60: 583-587.
25. Musicki B, Kramer MF, Becker RE, Burnett AL. Inactivation of phosphorylated endothelial nitric oxide synthase (Ser-1177) by O-GlcNAc in diabetes-associated erectile dysfunction. Proc Natl Acad Sci USA 2005; 102: 11870-11875.
26. Azadzoi KM, Kim N, Brown ML, Goldstein I, Cohen RA, Saenz de Tejada I. Endothelium-derived nitric oxide and cyclooxygenase products modulate corpus cavernosum smooth muscle tone. J Urol 1992; 147: 220-225.
27. Hamed EA, Meki AR, Gaafar AA, Hamed SA. Role of some vasoactive mediators in patients with erectile dysfunction: their relationship with angiotensin-converting enzyme and growth hormone. Int J Impot Res 2003; 15: 418-425.
28. Seftel AD, Vaziri ND, Ni Z, Razmjouei K, Fogarty J, Hampel N et al. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology 1997; 50: 1016-1026.
29. Cartledge JJ, Eardley I, Morrison JF. Nitric oxide-mediated corpus cavernosal smooth muscle relaxation is impaired in ageing and diabetes. BJU Int 2001; 87: 394-401.
30. Sullivan ME, Mumtaz FH, Dashwood MR, Thompson CS, Naseem KM, Bruckdorfer KR et al. Enhanced relaxation of diabetic rabbit cavernosal smooth muscle in response to nitric oxide: potential relevance to erectile dysfunction. Int J Impot Res 2002; 14: 523-532.
31. Sozmen B, Delen Y, Girgin FK, Sozmen EY. Catalase and paraoxonase in hypertensive type 2 diabetes mellitus: correlation with glycemic control. Clin Biochem 1999; 32: 423-427.
32. Khan MA, Thompson CS, Jeremy JY, Mumtaz FH, Mikhailidis P, Morgan RJ. The effect of superoxide dismutase on nitric oxide-mediated and electrical field-stimulated diabetic rabbit cavernosal smooth muscle relaxation. BJU Int 2001; 87: 98-103.
33. De Young L, Yu D, Freeman D, Brock GB. Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model. Int J Impot Res 2003; 15: 347-354.